When will Sotorasib be available in China?

Sotorasib is a new anti-cancer drug that provides a promising treatment option for patients with non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. Internationally, sotorasibu has been approved by some countries and is used to treat related cancers in some areas.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

As for its launch time in China, the specific launch time may be affected by multiple factors, including drug registration application approval, medical system regulations, drug pricing and market access, etc. Generally, drugs being marketed in China need to go through the approval process of the national drug regulatory authorities, which includes evaluation of the safety, effectiveness and quality of the drug.

The specific time of China's drug approval process is a dynamic process and will be affected by many factors. Generally speaking, drug developers try their best to speed up the approval process so that patients can benefit from new treatments sooner. In addition, the Chinese government has been strengthening its policies on the speed of approval and market access of innovative drugs in recent years to promote the early launch of new drugs and meet the medical needs of patients.

In order to obtain the latest information on the launch of sotorasibu in China, it is recommended that you check the official website of the National Medical Products Administration of China (NMPA), announcements from drug manufacturing companies, or consult medical professionals to obtain more accurate and up-to-date information.